Since Psych Capital’s IPO, the board has been reviewing the regulatory landscape and investment opportunities in the UK, Europe and further afield, including drug development and patient delivery pathways. It has been actively working with the CDPRG as part of its existing advisory agreement with them.
The expertise of the CDPRG in identifying regulatory barriers and opportunities, patient need, healthcare delivery frameworks, and political landscapes, has been instrumental as Psych Capital assesses a number of opportunities for strategic deployment of capital, leveraging its position as the first listed psychedelic company in London.
Psych Capital is on a mission to shape delivery pathways for psychedelic medicines to meet the significant unmet needs of patients in the UK and other markets, particularly in the context of an escalating mental health crisis.
William Potts, Chief Investment Officer, said: ‘Ahead of our next phase, we are delighted to add the CDPRG representative Crispin Blunt, a pioneering and leading healthcare politician leading the UK psychedelic health group, to our Psychedelic Medicines Technical Advisory Board, to augment our regulatory expertise, and to give us a seat at the table in shaping government policy.’
Psych Capital wants to be an active participant in shaping a delivery pathway for psychedelics, to meet the significant unmet needs of patients in the UK and other markets, particularly in the context of an escalating mental health crisis and revolutionise how society deals with mental health conditions. For more information, please visit the website: https://psych.capital